Posted by Michael Wonder on 05 Jun 2017
Deadline approaching
5 June 2017 - Final date close for submissions to controversial drug post-marketing review.
Tuesday, 6 July is the last day on which pharmacists can make a submission to a Government review that has called into question the way ezetimibe is prescribed and dispensed to patients with dyslipidemia who are inadequately controlled on, or unable to tolerate, statin therapy.
A draft Department of Health Post-market Review of ezetimibe claims that at least 18% of scripts written for the 300,000 Australians receiving the cholesterol lowering agent are outside the PBS restriction: requirement for titration of statins to maximum tolerated doses before initiating ezetimibe; or for use in patient with high CVD risk who experience an adverse event during treatment with a statin necessitating a reduction in the dose or withdrawal of the statin.
